Download PDF
Rofo 2007; 179(11): 1113-1126
DOI: 10.1055/s-2007-963285
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Transarterielle Chemoembolisation (TACE) des hepatozellulären Karzinoms: Technik, Indikationsstellung und Ergebnisse

Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma: Technique, Indication and ResultsT. J. Vogl1 , S. Zangos1 , J. O. Balzer1 , M. Nabil1 , P. Rao1 , K. Eichler1 , W. O. Bechstein2 , S. Zeuzem3 , A. Abdelkader1
  • 1Institut für Diagnostische und Interventionelle Radiologie, J. W. Goethe-Universität, Frankfurt
  • 2Klinik für Allgemeinchirurgie, J. W. Goethe-Universität, Frankfurt
  • 3Klinik für Innere Medizin, Hepatologie, J. W. Goethe-Universität, Frankfurt
Further Information

Publication History

eingereicht: 19.12.2006

angenommen: 24.5.2007

Publication Date:
19 October 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Vorstellung der Technik, Indikationsstellung und Ergebnisse der transarteriellen Chemoembolisation (TACE) des hepatozellulären Karzinoms (HCC). Dem Prinzip der TACE folgend, werden verschiedene Zytostatika in die A. hepatica injiziert, wie z. B. die Substanzen Doxorubicin, Cisplatin oder Mitomycin C. Als Embolisat wird in der Regel Lipiodol verwendet, zur temporären Gefäßokklusion Gelfoam oder abbaubare Mikrosphären. Die häufigsten Nebenwirkungen nach TACE stellen Fieber, Bauchschmerzen und Erbrechen dar, bis zu einem akuten/chronischen Leberversagen. Bei palliativer Indikation zeigt die TACE bei irresektablem HCC eine erfolgreiche Tumorkontrolle in 15 bis 60 % der Patienten und 5-Jahres-Überlebensraten von 8 - 43 %. Bei potenziell kurativer Indikation erlaubt die TACE eine lokale Tumorkontrollrate von 18 - 63 %. Bei neoadjuvanter (downsizing) Indikation in Kombination mit perkutaner Alkoholinstillation (PEI) oder Radiofrequenzablation (RFA) liegt die lokale Tumorkontrollrate bei 80 - 96 %. Vor Lebertransplantation eingesetzt, lassen sich 5-Jahres-Überlebensraten von 59 - 93 % erreichen. Die symptomatische Indikation ist gegeben, um Schmerzen und akuten/subakuten Blutungen beim HCC entgegenzuwirken. Das lokale Therapieansprechen liegt bei 88 % und Blutungskontrollraten bei 83 bis 100 % der Fälle. Schlussfolgerung: Bei lokalisiertem und diffusem HCC erlaubt der Einsatz der TACE spezifische symptomatische, palliative, potenziell kurative und neoadjuvante Therapieoptionen.

Abstract

To present current data on technique, indications and results of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). The principle of TACE is the intra-arterial injection of chemotherapeutic drug combinations like doxorubicin, cisplatin and mitomycin into the hepatic artery, followed by lipiodol injection, Gelfoam for vessel occlusion and degradable microspheres. The side effects and complications after TACE range from fever, upper abdominal pain and vomiting to acute or chronic liver cell failure. The palliative effect in unresectable HCC using TACE allows local tumor control in 15 to 60 % of cases and 5-year survival rates ranging from 8 - 43 %. The potentially curative treatment option allows local tumor control from 18 - 63 %. The neoadjuvant treatment option of TACE in combination with other treatment options like percutaneous ethanol injection (PEI) or radiofrequency ablation (RFA) reach local tumor control rates between 80 - 96 %. The bridging effect of TACE before liver transplantation reaches 5-year survival rates from 59 - 93 %. The symptomatic therapy option of TACE is used to counteract pain directly caused by HCC and acute/subacute bleeding in the HCC. The local tumor response reaches up to 88 % and the bleeding control is from 83 to 100 %. Conclusion: TACE is a potentially curative, palliative, neoadjuvant, bridging and symptomatic therapy option for local and diffuse HCC.

Key words

hepatic arteries - interventional procedures - transarterial chemoembolization

Literatur

  • 1 Poon R TP, Fan S T, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma.  Ann Surg. 2000;  232 10-24
    Google Scholar
  • 2 Bruix J, Castells A, Bosch J. et al . Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.  Gastroenterology. 1996;  111 1018-1022
    Google Scholar
  • 3 Ramsey D E, Kernagis L Y, Soulen M C. et al . Chemoembolization of Hepatocellular Carcinoma.  JVIR. 2002;  13 211-221
    Google Scholar
  • 4 Pugh R NH, Murray-Lyon I M, Dawson J L. et al . Transection of the oesophagus for bleeding of oesophageal varices.  Br J Surg. 1973;  60 646-649
    Google Scholar
  • 5 Okuda K, Ohtsuki T, Obata H. et al . Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients.  Cancer. 1985;  56 918-928
    Google Scholar
  • 6 The Cancer of the Liver Italian Program (CLIP) Investigators . A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients.  Hepatology. 1998;  28 751-755
    Google Scholar
  • 7 Ueno K, Miyazono N, Inoue H. et al . Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.  Cancer. 2000;  88 1574-1581
    Google Scholar
  • 8 Charnsangavej C. Chemoembolization of liver tumors.  Semin Invest Radiol. 1993;  10 150-160
    Google Scholar
  • 9 Lubienski A, Bitsch R G, Schemmer P. et al . Langzeitergebnisse der interventionellen Therapie von großen, inoperablen hepatozellulären Karzinomen (HCC): signifikanter Überlebensvorteil von transarterieller Chemoembolisation (TACE) und perkutaner Ethanolinjektion (PEI) gegenüber der TACE-Monotherapie.  Fortschr Röntgenstr. 2004;  176 1794-1802
    Google Scholar
  • 10 Zangos S, Gille T, Eichler K. et al . Transarterielle Chemoembolisation bei hepatozellulären Karzinomen: Technik, Indikationsstellung, Ergebnisse.  Radiologe. 2001;  41 906-914
    Google Scholar
  • 11 Lee K, Sung K, Lee D. et al . Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Anatomic and Hemodynamic Considerations in the Hepatic Artery and Portal Vein.  RadioGraphics. 2002;  22 1077-1091
    Google Scholar
  • 12 Raoul J L, Guyader D, Bretagne J F. et al . Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-labeled-iodized oil in the treatment of hepatocellular carcinoma.  Hepatology. 1997;  26 1156-1161
    Google Scholar
  • 13 Matsuo N, Uchida H, Sakaguchi H. et al . Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopatho logic findings.  Semin Oncol. 1997;  24 61-70
    Google Scholar
  • 14 Nakao N, Uchida H, Kamino K. et al . Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis.  Cardiovasc Intervent Radiol. 1994;  17 76
    Google Scholar
  • 15 Gerhards A, Mildenberger P, Herber S. et al . Möglicher Nutzen und Auswirkung einer Lipiodolmarkierung auf die Histologie beim hepatozellulären Karzinom.  Fortschr Röntgenstr. 2005;  177 1380-1386
    Google Scholar
  • 16 Hong-Yan  C, Yi  S, Xiang  W. et al . Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT.  World J Gastroenterol. 2004;  10 2753-2755
    Google Scholar
  • 17 Vogl T J, Trapp M, Schroeder H. et al . Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center.  Radiology. 2000;  214 349-357
    Google Scholar
  • 18 Basile A, Rand T, Lomoschitz F. et al . Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone Neoplasms.  Cardiovasc Intervent Radiol. 2004;  27 495-502
    Google Scholar
  • 19 Llovet J M, Real M I, Montana X. et al . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial.  Lancet. 2002;  359 1734-1739
    Google Scholar
  • 20 Rand T, Loewe C, Schoder M. et al . Arterial Embolization of Unresectable Hepatocellular Carcinoma with Use of Microspheres, Lipiodol, and Cyanoacrylate.  Cardiovasc Intervent Radiol. 2005;  28 313-318
    Google Scholar
  • 21 Gunji T, Kawauchi N, Akahane M. et al . Treatment of unresectable hepatocellular carcinoma less than 2 centimeters by transcatheter arterial chemoembolization with autologous blood clot.  J Clin Gastroenterol. 2003;  36 347-51
    Google Scholar
  • 22 Kwok P, Lam T W, Chan S. et al . A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma.  J Hepatol. 2000;  32 955-964
    Google Scholar
  • 23 Lewis A L, Gonzalez M V, Lloyd A W. et al . DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization.  JVIR. 2006;  17 335-342
    Google Scholar
  • 24 Solomon B, Soulen M C, Baum R A. et al . Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U. S. population.  JVIR. 1999;  10 793-798
    Google Scholar
  • 25 Konno T, Maeda H, Iwai K. et al . Effect of arterial administration of high-molecular-wight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.  Eur J Cancer Clin Oncol. 1983;  19 1053-1065
    Google Scholar
  • 26 Horiguchil Y, Itohl M, Takagawa H. et al . Chemotherapy and Pharmacology Assessment of chemoembolization therapy for primary liver cancer using a stabilized A driamycin-lipiodol suspension.  Cancer Chemother Pharmacol. 1992;  31 60-64
    Google Scholar
  • 27 Takayusa K, Shima Y, Muramatsu Y. et al . Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.  Radiology. 1987;  163 345
    Google Scholar
  • 28 Nakamura N, Hashimoto T, Oi H. et al . Transcatheter oily chemoembolization of hepatocellular carcinoma.  Radiology. 1989;  170 783
    Google Scholar
  • 29 Pelletier G, Ducreux M, Gay F. et al . Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial.  J Hepatol. 1998;  29 129-134
    Google Scholar
  • 30 Kamada K, Nakanishi T, Kitamoto M. et al . Long-term Prognosis of Patients Undergoing Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Comparison of Cisplatin Lipiodol Suspension and Doxorubicin Hydrochloride Emulsion.  J Vasc Interv Radiol. 2001;  12 847-854
    Google Scholar
  • 31 Cejna M. Chemoembolisation bei hepatozellulärem Karzinom (HCC).  J Gastroenterol Hepatol. 2006;  5 12-16
    Google Scholar
  • 32 Sakamoto I, Nobuya A, Nagaoki K. et al . Complications associated with transcatheter arterial embolization for hepatic tumors.  Radiographics. 1998;  18 605-619
    Google Scholar
  • 33 Leung D, Goin J, Sickles C. et al . Determinants of Postembolization Syndrome after Hepatic Chemoembolization.  J Vasc Interv Radiol. 2001;  12 321-326
    Google Scholar
  • 34 Chung J W, Park J H, Han J K. et al . Hepatic tumors: predisposing factors for complications of transarterial oily chemoembolization.  Radiology. 1996;  198 33-40
    Google Scholar
  • 35 Patel N H, Hahn D, Rapp S. et al . Hepatic artery embolization: factors predisposing to postembolization pain and nausea.  J Vasc Interv Radiol. 2000;  11 453-460
    Google Scholar
  • 36 Miyoshi S, Minami Y, Kawata S. et al . Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma. Assessment by maximal removal rate of indocyanine green.  J Hepatol. 1988;  6 332-336
    Google Scholar
  • 37 Huang Y H, Chen C H, Chang T T. et al . The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multi-center study.  Liver Int. 2004;  24 419-24
    Google Scholar
  • 38 Huppert P E, Lauchart W, Duda S H. et al . Chemoembolisation des hepatozellulären Karzioms: Welche Faktoren bestimmen Therapieansprechen und Überleben?.  Fortschr Röntgenstr. 2004;  176 375-385
    Google Scholar
  • 39 Uraki J, Yamakado K, Nakatsuka A. et al . Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors.  Eur J Radiol. 2004;  51 12-18
    Google Scholar
  • 40 Yuen M F, Chan A O, Wong B C. et al . Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.  Am J Gastroenterol. 2003;  98 1181-1185
    Google Scholar
  • 41 Grieco A, Marcoccia S, Miele L. et al . Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.  Hepatogastroenterology. 2003;  50 207-212
    Google Scholar
  • 42 El Khaddari S, Gaudin J L, Abidi H. et al . Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session.  Gastroenterol Clin Biol. 2002;  26 728-734
    Google Scholar
  • 43 Ikeda K, Kumada H, Saitoh S. et al . Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma.  Cancer. 1991;  68 2150-2154
    Google Scholar
  • 44 Majno P E, Adam R, Bismuth H. et al . Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.  Ann Surg. 1997;  226 688-701
    Google Scholar
  • 45 Sugo H, Futagawa S, Beppu T. et al . Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence.  World J Surg. 2003;  27 1295-1299
    Google Scholar
  • 46 Mazzaferro V, Regalia E, Doci R. et al . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  334 693-699
    Google Scholar
  • 47 Llovet J M, Mas X, Aponte J J. et al . Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.  Gut. 2002;  50 123-128
    Google Scholar
  • 48 Herber S, Schneider J, Brecher B. et al . TACE: Therapie des HCC vor Lebertransplantation - Erfahrungen.  Fortschr Röntgenstr. 2005;  177 681-690
    Google Scholar
  • 49 Yao F Y, Ferrell L, Bass N M. et al . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.  Hepatology. 2001;  33 1394-1403
    Google Scholar
  • 50 Richard III H M, Silberzweig J E, Mitty H A. et al . Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma.  Radiology. 2000;  214 775
    Google Scholar
  • 51 Sotiropoulos G C, Malago M, Molmenti E. et al . Efficacy of transarterial chemoembolization prior to liver transplantation for hepatocellular carcinoma as found in pathology.  Hepatogastroenterology. 2005;  52 329-332
    Google Scholar
  • 52 De Carlis L, Giacomoni A, Lauterio A. et al . Liver transplantation for hepatocellular cancer: should the current indication criteria be changed?.  Transpl Int. 2003;  16 115-122
    Google Scholar
  • 53 Lesurtel M, Mullhaupt B, Pestalozzi B C. et al . Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence-based Analysis.  American Journal of Transplantation. 2006;  6 2644-2650
    Google Scholar
  • 54 Omata M, Tateishi R, Haruhiko Y. et al . Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation.  Gastroenterology. 2004;  127 159-166
    Google Scholar
  • 55 Tanaka K, Okazaki H, Nakamura S. et al . Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection.  Radiology. 1991;  179 713-717
    Google Scholar
  • 56 Jansen M C, Hillegersberg van R, Chamuleau R A. et al . Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review.  Eur J Surg Oncol. 2005;  31 331-347
    Google Scholar
  • 57 Koda M, Murawaki Y, Oyama K. et al . Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma.  Cancer. 2001;  92 1516-1524
    Google Scholar
  • 58 Becker G, Soezgen T, Olschewski M. et al . Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma.  World J Gastroenterol. 2005;  11 6104-6109
    Google Scholar
  • 59 Bartolozzi C, Lencioni R, Caramella D. et al . Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization.  Radiology. 1995;  197 812-818
    Google Scholar
  • 60 Buscarini E, Savoia A, Brambilla G. et al . Radiofrequency thermal ablation of liver tumors.  Eur Radiol. 2005;  15 884-894
    Google Scholar
  • 61 Clasen S, Pereira P L. Radiofrequenzablation von Lungentumoren.  Fortschr Röntgenstr. 2006;  178 852-861
    Google Scholar
  • 62 Ahrar K, Newmann R A, Pang J. et al . Dr. Gary J. Becker Young Investigator Award: relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization.  J Vascular Interv Radiol. 2004;  15 901-905
    Google Scholar
  • 63 Veltri A, Moretto P, Doriguzzi A. et al . Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).  Eur Radiol. 2006;  16 661-669
    Google Scholar
  • 64 Hansler J, Frieser M, Schaber S. et al . Radiofrequency ablation of hepatocellular carcinoma with a saline solution perfusion device: a pilot study.  J Vasc Interv Radiol. 2003;  14 575-580
    Google Scholar
  • 65 Yamakado K, Nakatsuka A, Ohmori S. et al . Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology.  J Vasc Interv Radiol. 2002;  13 1225-1232
    Google Scholar
  • 66 Kühl H, Stattaus J, Kühl B. et al . Radiofrequenzablation von malignen Lebertumoren: Erlaubt ein volumetrischer Nekrose-/Tumor-Quotient eine Vorhersage zur lokalen Tumorkontrolle?.  Fortschr Röntgenstr. 2006;  178 1243-1249
    Google Scholar
  • 67 Porrett P M, Peterman H. Lack of benefit of pretranspant locoregional hepatic therapy for hepatocellular cancer in the current MELD era.  J Vasc Interv Radiol. 2006;  17 1070
    Google Scholar
  • 68 Vogl T J, Straub R, Eichler K. et al . Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions).  Radiology. 2002;  225 367-377
    Google Scholar
  • 69 Vogl T J, Mack M, Straub R. et al . Thermische Ablation von Lebermetastasen: Aktueller Stand und Perspektiven.  Radiologe. 2001;  41 49-55
    Google Scholar
  • 70 Pacella C M, Bizzarri G, Cecconi P. et al . Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization.  Radiology. 2001;  219 669-678
    Google Scholar
  • 71 Zangos S, Eichler K, Balzer J O. et al . Large-sized hepatocelullar carcinoma (HCC): Neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser induced thermotherapy (LITT).  Eur Radiol. 8.8.2006 [Epub ahead of print]; 
    Google Scholar
  • 72 Miyamoto M, Sudo T, Kuyama T. Spontaneous rupture of hepatocellular carcinoma: a review of 172 Japanese cases.  Am J Gastroenterol. 1991;  86 67-71
    Google Scholar
  • 73 Liu C L, Fan S T, Lo C M. et al . Management of Spontaneous Rupture of Hepatocellular Carcinoma: Single-Center Experience.  J Clin Oncol. 2001;  19 3725-3732
    Google Scholar
  • 74 Ong G B, Taw J L. Spontaneous rupture of hepatocellular carcinoma.  BMJ. 1972;  4 146-149
    Google Scholar
  • 75 Ngan H, Tso W K, Lai C L. et al . The role of hepatic arterial embolization in the treatment of spontaneous rupture of hepatocellular carcinoma.  Clin Radiol. 1998;  53 338-41
    Google Scholar
  • 76 Kulik L M, Atassi B, Van Hosbeeck L. et al . Yttrium-90 Microspheres (TheraSphere®) Treatment of Unresectable Hepatocellular Carcinoma: Downstaging to Resection, RFA and Bridge to Transplantation.  J Surg Oncol. 2006;  94 572-586
    Google Scholar
  • 77 Huang Y H, Wu J C, Chen S C. et al . Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter.  Aliment Pharmacol Ther. 2006;  23 129-135
    Google Scholar
  • 78 Liem M S, Poon R T, Lo C M. et al . Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation.  World J Gastroenterol. 2005;  11 4465-4471
    Google Scholar
  • 79 Chung Y H. A strategy for early detection of recurrent hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization.  Intervirology. 2005;  48 46-51
    Google Scholar
  • 80 Greten T F, Papendorf F, Bleck J S. et al . Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.  Br J Cancer. 2005;  92 1862-1868
    Google Scholar
  • 81 Sumie S, Yamashita F, Ando E. et al . Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.  Am J Roentgenol. 2003;  181 1327-1334
    Google Scholar
  • 82 Maeda S, Shibata J, Fujiyama S. et al . Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.  Hepatogastroenterology. 2003;  50 809-813
    Google Scholar
  • 83 Junji F, Hiroshi I, Mitsuo S. et al . Pilot Study of Transcatheter Arterial Chemoemblization with Degradable Starch Microspheres in Patients with Hepatocellular Carcinoma.  Am J Clin Oncol. 2003;  26 159-164
    Google Scholar
  • 84 O’Suilleabhain C B, Poon R TB, Yong J L. et al . Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.  British Journal of Surgery. 2003;  90 325-331
    Google Scholar
  • 85 Ebied O M, Federle M P, Carr B I. et al . Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma.  Cancer. 2003;  97 1042-1050
    Google Scholar
  • 86 Saccheri S, Lovaria A, Sangiovanni A. et al . Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas.  J Vasc Interv Radiol. 2002;  13 995-999
    Google Scholar
  • 87 Achenbach T, Seifert J K, Pitton M B. et al . Chemoembolization for primary liver cancer.  Eur J Surg Oncol. 2002;  28 37-41
    Google Scholar
  • 88 Fan J, Tang Z Y, Yu Y Q. et al . Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.  Dig Surg. 1998;  15 674-678
    Google Scholar
  • 89 Poyanli A, Rozanes I, Acunas B. et al . Palliative treatment of hepatocellular carcinoma by chemoembolization.  Acta Radiol. 2001;  42 602-607
    Google Scholar
  • 90 Takayasu K, Arii S, Matsuo N. et al . Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma.  Am J Roentgenol. 2000;  175 699-704
    Google Scholar
  • 91 Liado L, Virgill J, Figueras J. et al . A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.  Cancer. 2000;  88 50-57
    Google Scholar
  • 92 Savastano S, Miotto D, Casarrubea G. et al . Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child’s grade A or B cirrhosis: a multivariate analysis of prognostic factors.  J Clin Gastroenterol. 1999;  28 334-340
    Google Scholar
  • 93 Shah S R, Riordan S M, Karani J. et al . Tumor ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma.  QJM. 1998;  91 821-828
    Google Scholar
  • 94 Carr B. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients.  Hepatogastroenterol. 2002;  49 79-86
    Google Scholar
  • 95 Ren Z G, Lin Z Y, Xia J L. et al . Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study.  World J Gastroenterol. 2004;  10 2791-2794
    Google Scholar
  • 96 Ren Z, Lin Z, Ye S. Transcatheter arterial chemoembolization for postoperative residual tumor of hepatocellular carcinoma.  Zhonghua Zhong Liu Za Zhi. 2001;  23 332-334
    Google Scholar
  • 97 Lin Z, Ren Z, Xia J. Appraisal of postoperative transcatheter arterial chemoembolization (TACE) for prevention and treatment of hepatocellular carcinoma recurrence.  Zhonghua Zhong Liu Za Zhi. 2000;  22 315-317
    Google Scholar
  • 98 Zhang Z, Liu Q, He J. et al . The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma.  Cancer. 2000;  89 2606-2612
    Google Scholar
  • 99 Gerunda G E, Neri D, Merenda R. et al . Role of transarterial chemoembolization before liver resection for hepatocellular carcinolma.  Liver Transpl. 2000;  6 619-626
    Google Scholar
  • 100 Chen X M, Luo P F, Lin H H. et al . Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma.  Ai Zheng. 2004;  23 829-832
    Google Scholar
  • 101 Huo T I, Huang Y H, Wu J C. et al . Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study.  Ann Oncol. 2003;  14 1648-1653
    Google Scholar
  • 102 Li Y H, Wang C S, Liao L Y. et al . Long-term survival of Taiwanese patients with hepatocellular carcinoma after combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection.  J Formos Med Assoc. 2003;  102 141-146
    Google Scholar
  • 103 Kamada K, Kitamoto M, Aikata H. et al . Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma.  Am J Surg. 2002;  184 284-290
    Google Scholar
  • 104 Li C, Shi Z, Hao Y. Combined percutaneous ethanol injection through liver puncture and transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma.  Zhonghua Zhong Liu Za Zhi. 2001;  23 490-492
    Google Scholar
  • 105 Dohmen K, Shirahama M, Shigematsu H. et al . Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.  Hepatogastroentereology. 2001;  48 1409-1415
    Google Scholar
  • 106 Lencioni R, Paolicchi A, Moretti M. et al . Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate.  Eur Radiol. 1998;  8 439-444
    Google Scholar
  • 107 Tanaka K, Nakamura S, Numata K. et al . The long-term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis.  Cancer. 1998;  82 78-85
    Google Scholar
  • 108 Yamakado K, Nakatsuka A, Akeboshi M. et al . Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: Short-term recurrences and survival.  Oncol Rep. 2004;  11 105-109
    Google Scholar
  • 109 Bloomston M, Binitie O, Fraiji E. et al . Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy.  Am Surg. 2002;  68 827-831
    Google Scholar

Prof. Thomas J. Vogl

Institut für Diagnostische und Interventionelle Radiologie, J. W. Goethe-Universität Frankfurt

Theodor-Stern-Kai 7

60596 Frankfurt

Phone: ++49/69/63 01 72 77

Fax: ++49/69/63 01 72 58

Email: T.vogl@em.uni-frankfurt.de

      >